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Abstract: Background: Skeletal muscle (SM) mitochondrial dysfunction, oxidative stress, inflammation and
muscle mass loss may worsen prognosis in chronic heart failure (CHF). Diet-induced obesity may also
cause SM mitochondrial dysfunction as well as oxidative stress and inflammation, but obesity per se
may be paradoxically associated with high SM mass and mitochondrial adenosine triphosphate (ATP)
production, as well as with enhanced survival in CHF. Methods: We investigated interactions between
myocardial infarction(MI)-induced CHF and diet-induced obesity (12-wk 60% vs. standard 10% fat)
in modulating gastrocnemius muscle (GM) mitochondrial ATP and tissue superoxide generation,
oxidized glutathione (GSSG), cytokines and insulin signalling activation in 10-wk-old mice in
the following groups: lean sham-operated, lean CHF (LCHF), obese CHF (ObCHF; all n = 8).
The metabolic impact of obesity per se was investigated by pair-feeding ObCHF to standard diet with
stabilized excess body weight until sacrifice at wk 8 post-MI. Results: Compared to sham, LCHF had
low GM mass, paralleled by low mitochondrial ATP production and high mitochondrial reative
oxygen species (ROS) production, pro-oxidative redox state, pro-inflammatory cytokine changes and
low insulin signaling (p < 0.05). In contrast, excess body weight in pair-fed ObCHF was associated with
high GM mass, preserved mitochondrial ATP and mitochondrial ROS production, unaltered redox
state, tissue cytokines and insulin signaling (p = non significant vs. Sham, p < 0.05 vs. LCHF) despite
higher superoxide generation from non-mitochondrial sources. Conclusions: CHF disrupts skeletal
muscle mitochondrial function in lean rodents with low ATP and high mitochondrial ROS production,
associated with tissue pro-inflammatory cytokine profile, low insulin signaling and muscle mass loss.
Following CHF onset, obesity per se is associated with high skeletal muscle mass and preserved
tissue ATP production, mitochondrial ROS production, redox state, cytokines and insulin signaling.
These paradoxical and potentially favorable obesity-associated metabolic patterns could contribute to
reported obesity-induced survival advantage in CHF.
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1. Introduction
Chronic heart failure (CHF) is a major cause of morbidity and mortality in the general
population, with increasing prevalence worldwide [1–3]. Besides the severity of myocardial dysfunction,
CHF patients’ outcome is strongly and negatively influenced by loss of skeletal muscle mass and
function [4–9], and a pattern of metabolic abnormalities affecting tissue energy metabolism and
anabolic responses is emerging as a relevant contributor to skeletal muscle derangements [10–16].
In particular, metabolic changes may reportedly include mitochondrial dysfunction, altered redox
state, inflammation and insulin resistance [12,17–24]. Some although not all reports have further
suggested that metabolic alterations, particularly those involving mitochondrial function and redox
state, are more pronounced in skeletal muscle in CHF patients with reduced compared to preserved
ejection fraction [25]. Indeed, we recently showed that myocardial infarction-induced CHF with
reduced ejection fraction leads to low mitochondrial oxidative enzyme activities, associated with
pro-inflammatory transcription factors activation and low insulin signaling [26] that might directly
impair skeletal muscle performance and anabolism [13]. Mitochondrial changes could also contribute to
enhance reactive oxygen species generation [12,27,28], which might per se further enhance inflammation,
insulin resistance, further mitochondrial dysfunction, excitation-contraction uncoupling and ultimately
muscle catabolism [20,27,29–32].
Mechanisms underlying CHF-induced skeletal muscle metabolic abnormalities and catabolism
remain only partly explored while, based on the above considerations their understanding is a major
research and clinical priority. Nutritional status is a potential major modulator of skeletal muscle
metabolism, but little is known on its muscle metabolic impact in CHF. In recent years obesity has
been paradoxically associated with better outcomes and enhanced survival in CHF, but potential
interactions between obesity and CHF to differentially modulate skeletal muscle metabolic responses
remain unknown [4,13,33–35]. Although its long-term metabolic complications include skeletal
muscle oxidative stress, inflammation and insulin resistance [28,36,37], fat-induced enhancement of
mitochondrial biogenesis and high muscle mitochondrial oxidation capacity have been reported in
experimental and clinical obesity models [38,39]. Intriguingly, no changes or even increases in insulin
signaling activation may also characterize early obesity stages in a time-dependent fashion [40–42].
In addition and also importantly, epidemiological studies have reported enhanced skeletal muscle
mass in obese individuals to parallel increments of total body mass [43]. In the current study we
therefore investigated interactions between myocardial infarction-induced CHF with reduced ejection
fraction and high-fat diet-induced obesity (60% vs. standard 10% dietary calories as fat) in modulating
mitochondrial adenosine triphosphate (ATP) and reactive oxygen species (ROS) generation at various
cellular levels, tissue redox state markers, pro- and anti-inflammatory cytokines and insulin signaling
protein activation. To this aim, myocardial infarction was induced by coronary artery ligation in
10-wk-old lean or high-fat diet-induced obese mice. In order to investigate the role of obesity per se
and to prevent potential confounding effects of simultaneous high-fat feeding (High-Fat-Metabolism),




Thirty10-week-old male CD1 mice (Harlan, San Piero al Natisone, Italy) mice were randomly
assigned to the following diets which were administered ad libitum: standard (Harlan 2018, Fat = 9%
total calories, L, n = 20) or high-fat diet (Harlan TD.6414, Fat = 60% total calories, Ob, n = 10). Mice were
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kept at constant temperature and humidity and exposed to 12 h light/dark cycles in the International
Centre for Genetic Engineering and Biotechnology (ICGEB, Trieste, Italy) animal facility. The study
was conducted in compliance with national and international laws and policies. Study design and
procedures were approved by the ICGEB Animal Welfare Board and Ethical Committee and by the
National Animal Experimentation Authority (6442015PR). After 12 weeks, heart failure was induced in
8 animals from each diet by permanent left anterior descending (LAD) coronary artery ligation (n = 11
each group, CHF) as previously described [44,45]. Briefly, after anesthesia was induced with ketamine
(100 mg kg−1) and xylazine (10 mg kg−1), mice were placed on a warmed pad to maintain body
temperature, an endothracheal tube was placed and were mechanically ventilated (Model 131 rodent
ventilator, Nemi Scientific Inc., Medway, MA, USA). Following left thoracotomy, pericardiotomy and
heart exposure, LAD descendent branch was ligated with an 8-0 silk suture under stereomicroscope
(Leica) visualization. Following MI confirmation by observation of left ventricle’s anterior wall
whitening, the chest was closed and mice allowed to recover spontaneous breathing. The other
animals were treated with sham operation (S). To further evaluate cardiac function and confirm CHF,
2-D transthoracic echocardiography was performed using a Vevo 770 Ultrasound (Visualsonics, Bothell,
WA, USA) device with a 30-MHz linear array transducer, both after surgery and one week before
sacrifice. Animals who underwent LAD ligature but whose left ventricular ejection fraction (LVEF)
was not reduced to <50% were excluded from the study, leaving n = 8 animals/group. As expected,
all sham operated animals had LVEF >50%. Following operation, all mice were pair-fed with standard
diet to assess the impact of obesity per se on investigated parameters. Mice were sacrificed at week 20,
three hours after food was removed, following anesthesia induction [27]. Left gastrocnemius muscle
was then surgically isolated, explanted, cleansed and weighed. Blood collected by heart puncture in
EDTA vials and placed in ice until separation by centrifugation. Epididimal fat pads and retroperitoneal
fat was isolated by careful microdissection and weighted. Tissue samples were the placed in iced saline
solution for immediate transfer to the laboratory performing ex-vivo assessments, or snap-frozen in
liquid nitrogen for further analyses [28].
2.2. Blood Glucose
Plasma glucose was determined by standard enzymatic-colorimetric assay [29].
2.3. Mitochondrial Function
ATP synthesis rate in isolated mitochondria was measured ex-vivo in freshly isolated mitochondria
by luciferin-luciferase luminescence assay in a microplate luminometer (Synergy 2 SL, BioTek, Winooski,
VT, USA) as previously described [26,28]. Several combinations of respiratory substrates were
contemporarily tested using the following final reaction concentrations (mmol/L): 0.25 pyruvate,
0.0125 palmitoyl-L-carnitine, 2.5 α-ketoglutarate, 0.25 malate (PPKM); 0.025 palmitoyl-L-carnitine,
0.5 malate (PCM); 20 succinate, 0.1 rotenone (SR); 10 glutamate, 5 malate (GM). Measurements
obtained were normalized by sample citrate synthase activity, measured spectrophotometrically as
referenced [28].
2.4. Superoxide Generation and Redox State
Superoxide anion generation in gastrocnemius lateralis was measured ex-vivo in tissue homogenate
using the lucigenin chemiluminescent method as referenced [27,46,47]. Differences between groups
in superoxide production from specific sources were assessed by measuring the impact of the
addition of a source-specific inhibitor on superoxide-related light emission from tissue homogenate
incubated with a source-specific substrate. In detail the following inhibitor/substrate combinations
were used for each of the following superoxide generation sources: uncoupling agent Carbonyl
cyanide m-chlorophenyl hydrazone (5 µmol/L)/respiratory substrate succinate (10 mmol/L) for
mitochondria; 200 µmol/L Diphenylhydantoin (DPI)/1 mmol/L Nicotinamide adenine dinucleotide
phosphate (NADPH) for NADPH-oxidase and 200 µmol/L Oxypurinol/500 µmol/L Xanthine for
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xanthine oxidase. Sample protein content (Bicinchoninic acid assay, Pierce, Rockford, IL, USA) was
used to normalize results prior to comparison.
Tissue total and oxidized glutathione were assessed spectrophotometrically on ~50 mg of
gastrocnemius muscle homogenized in 5% (wt/vol.; +4 ◦C) metaphosphoric acid, using the
5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB) conversion rate method as previously described [28,48].
To measure the oxidated fraction (GSSG), samples were previously incubated with 2-vynilpiridin 10%
(v/v) and subsequently neutralized by addition of triethanolamine 16.6% (v/v) [27].
2.5. Protein Expression and Phosphorylation
Tissue cytokine levels and insulin signaling and protein anabolism signaling activation were
measured using high-throughput xMAP magnetic beads technology with a Magpix reader (Luminex,
Austin, TX, USA). Commercial kits used to determine both cytokine profile and insulin signaling
protein expression and phosphorylation at Insulin receptor substrate 1 (IRS-1S312), Protein kinase B
(AKTS473), Glycogen synthase kinase 3β (GSK-3βS9), mammalian target of rapamycin (mTORS2448),
Proline-rich AKT substrate protein (PRAS40T246) and Ribosomal protein S6 kinase (P70S6KT421/S424)
were purchased form Millipore (Billerica, MA, USA) and used according to manufacturer’s instructions
as previously published [27,28,36]. Data were analyzed using Milliplex Analyst software (Millipore,
Billerica, MA, USA). Phosphorylation of insulin signaling pathway effectors is expressed as a
phospho-protein/expression of the same protein ratio. Cytokine levels are normalized by homogenate
protein content.
2.6. Statistical Analysis
Groups were compared using a Student t-test for unpaired or paired data or One-Way ANOVA
for unpaired data followed by a Tukey post-hoc test, as appropriate. p values < 0.05 were considered
statistically significant. Analysis was performed using GraphPad Prism v.5, GraphPad Software,
San Diego, CA, USA.
3. Results
3.1. Calorie Intake, Body and Tissue Weight and Plasma Glucose
Calorie intake: before MI and CHF induction, calorie intake was comparable by design in the two
groups receiving control diet, with markedly higher intake in the high-fat diet group. After MI and
CHF induction, ObCHF were switched to control diet by design, resulting in comparable caloric intake
to Sham and LCHF (p = NS; Table 1).
Table 1. Animal characteristics. Impact of previous 12-weeks diet-induced obesity in a mouse model
after myocardial infarction-induced chronic heart failure and 8-week pair-feeding (ObCHF) on body
weight, caloric intake, fat pads mass and plasma glucose levels compared to chronic heart failure (CHF)
and previously lean (LCHF) and to lean sham operated animals (Sham). Data timings refer to study
start (week 0: T0), surgical CHF induction (week 12: T12) and sacrifice (week 20: T20). p < 0.05 among
groups not sharing a letter. * p < 0.05 vs. T0; mean ± standard error of mean (SEM), n = 8/group.
Sham LCHF ObCHF
Body Weight [g] T0 42.0 ± 1.5 a 42.4 ± 0.9 a 41.9 ± 1.6 a
Body Weight [g] T12 44.1 ± 1.2 a 43.1 ± 1.3 a 53.0 ± 0.9 b,*
Body Weight [g] T20 46.9 ± 1.3 a,* 43.9 ± 1.1 b 53.6 ± 1.4 c,*
Average daily caloric intake (kcal/d) T0-T12 7.7 ± 0.6 a 7.8 ± 0.3 a 25.5 ± 4.1 b
Average daily caloric intake (kcal/d) T13-T20 7.7 ± 0.9 a 8.1 ± 0.4 a 8.9 ± 2.1 a,*
Left Retroperitoneal Fat Pad mass [mg] T20 294 ± 70 a 249 ± 58 b 493 ± 72 c
Left Epididimal Fat Pad mass [mg] T20 1031 ± 161 a 675 ± 162 b 1351 ± 126 c
Plasma Glucose [mg/dl] T20 131 ± 4 a 140 ± 3 a 155 ± 3 b
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Body weight: following dietary interventions and before MI induction, body weight was comparable
in groups receiving control diet while it was expectedly markedly higher in high-fat diet-fed animals.
Final body weight at sacrifice was lower in LCHF than in Sham. In ObCHF, body weight remained higher
than in both Sham and LCHF groups, but it did not increase compared to weight before MI and
CHF induction.
Tissue weight: Compared to the Sham group, gastrocnemius muscle (GM) weight was lower
in LCHF whereas it was highest in ObCHF (Figure 1A). GM weight was also found to be higher in
ObCHF when normalized by total body weight (Figure 1B). Compared to Sham, left retroperitoneal
and epididimal fat pads were comparable or lower in LCHF. In contrast, they were comparable or
higher in ObCHF (Table 1).
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Figure 1. Muscle mass. Impact of previous 12-weeks diet-induced obesity in a mouse model after 
myocardial infarction-induced chronic heart failure and 8-week pair-feeding (ObCHF) on left 
gastrocnemius muscle mass compared to previously lean (LCHF) and to lean sham operated animals 
(Sham) in absolute (A) or relative to body weight (B) values. p < 0.05 among groups not sharing a 
letter, mean ± standard error of mean (SEM), n = 8/group. 
3.2. Skeletal Muscle Mitochondrial ATP and ROS Production  
Compared to Sham, LCHF animals had lower GM mitochondrial ATP production capacity 
(Figure 2) and high tissue total and mitochondrial superoxide production (Figure 3). In contrast, 
skeletal muscle ATP production was preserved in ObCHF (Figure 2) with mitochondrial superoxide 
comparable to the Sham group. High total GM superoxide production in ObCHF was conversely 
entirely attributable to non-mitochondrial sources including Nitric Oxide Synthase (NOS) and 
Xanthine Oxidase (Figure 3). GM tissue redox state as reflected by oxidized over total glutathione 
(GSSG/GSH+GSSG) was more pro-oxidative in LCHF and comparable in Sham and ObCHF (Figure 
3). 
Figure 1. Muscle mass. Impact of previous 12-weeks diet-induced obesity in a mouse model
after myocardial infarction-induced chronic heart failure and 8-week air-feeding (ObCHF) on left
gastrocnemius muscle mass compared to previously lean (LCHF) and to lean sham operated animals
(Sham) in absolute (A) or relative to body weight (B) values. p < 0.05 among groups not sharing a letter,
mean ± standard error of mean (SEM), n = 8/group.
Plasma glucose: plasma glucose was comparable in the Sham and LCHF groups while it was
higher in ObCHF.
3.2. Skeletal Muscle Mitochondrial ATP and ROS Production
Compared to Sham, LCHF animals had lower GM mitochondrial ATP production capacity
(Figure 2) and high tissue total and mitochondrial superoxide production (Figure 3). In contrast,
skeletal muscle ATP production was preserved in ObCHF (Figure 2) with mitochondrial superoxide
comparable to the Sham group. High total GM superoxide production in ObCHF was conversely entirely
attributable to non-mitochondrial sources including Nitric Oxide Synthase (NOS) and Xanthine Oxidase
(Figure 3). GM tissue redox state as reflected by oxidized over total glutathione (GSSG/GSH+GSSG)
was more pro-oxidative in LCHF and comparable in Sham and ObCHF (Figure 3).
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Gastrocnemius muscle cytokine patterns paralleled those observed in mitochondrial superoxide 
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Figure 3. Muscle superoxide generation and redox state. Impact of previous 12-weeks diet-induced
obesity in a mouse model after myocardial infarction-induced chronic heart failure and 8-week
pair-feeding (ObCHF) on left gastrocnemius (A) total tissue, (B) mitochondria-, (C) uncoupled nitric
oxide synthase (NOS)-, (D) Nicotinamide adenine dinucleotide phosphate oxidase (NADPHox)- and
(E) Xanthine oxydase (Xox)-related superoxide generation as well as on (F) total and (G) oxydated
(GSSG) over total (GSSG+GSH) tissue glutathione compared to previously lean (LCHF) and to lean
sham operated animals (Sham). p < 0.05 among groups not sharing a letter, mean ± standard error of
mean (SEM), n = 8/group.
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3.3. Skeletal Muscle Cytokine Profile
Gastrocnemius muscle cytokine patterns paralleled those observed in mitochondrial superoxide
emission. In particular, despite absolute levels of tested pro-inflammatory cytokines were comparable
among groups, LCHF had selectively low anti-inflammatory IL-10 with unbalanced ratios to
pro-inflammatory cytokines (IL-10/TNFα) compared to Sham. In contrast, ObCHF had preserved
cytokine patterns compared to Sham animals (Figure 4).
3.4. Skeletal Muscle Insulin Signalling
Gastrocnemius muscle activating phosphorylations of insulin signaling protein also reflected
opposite changes in mitochondrial superoxide production and pro-inflammatory cytokine patterns.
In particular, compared to Sham LCHF had selectively low phosphorylated AKT and GSK-3β with
similar PRAS40 and P70S6K, while ObCHF had preserved phosphorylated AKT and GSK-3β and high
phosphorylated PRAS40 and P70S6K (Figure 5). Total protein levels did not differ among study groups
in the current model (data not shown).
Nutrients 2020, 11, x FOR PEER REVIEW 8 of 16 
 
co parable among groups, LCHF had selectively low anti-inflammatory IL-10 with unbalanced 
ratios to pro-inflammatory cytokines (IL-10/TNFα) compared to Sham. In contrast, ObCHF had 
preserved cytokine patterns compared to Sham animals (Figure 4).  
 
Figure 4. Muscle cytokine profile. Impact of previous 12-weeks diet-induced obesity in a mouse model 
after myocardial infarction-induced chronic heart failure and 8-week pair-feeding (ObCHF) on left 
gastrocnemius tissue protein levels of pro-inflammatory Interelukin (IL) 1β and 6 and Tumor Necrosis 
Factor α (TNFα), anti-inflammatory IL-10 and anti-inflammation index IL-10/TNFα ratio compared 
to previously lean (LCHF) and to lean sham operated animals (Sham). p < 0.05 among groups not 
sharing a letter, mean ± standard error of mean (SEM), n = 8/group. 
3.4. Skeletal Muscle Insulin Signalling 
Gastrocnemius muscle activating phosphorylations of insulin signaling protein also reflected 
opposite changes in mitochondrial superoxide production and pro-inflammatory cytokine patterns. 
In particular, compared to Sham LCHF had selectively low phosphorylated AKT and GSK-3β with 
similar PRAS40 and P70S6K, while ObCHF had preserved phosphorylated AKT and GSK-3β and 
high phosphorylated PRAS40 and P70S6K (Figure 5). Total protein levels did not differ among study 
groups in the current model (data not shown). 
uscle cyt i r fi I act of previ s 12- i t i
i
fl l i )
, a ti-infla atory IL-10 and anti- nflam ation index IL-10/TNFα ratio compared to
previously lean (LCHF) and to lean sham operated animals (Sham). p < 0.05 among groups not sharing
a letter, mean ± standard error of mean (SEM), n = 8/group.
Nutrients 2020, 12, 3393 9 of 16
Nutrients 2020, 11, x FOR PEER REVIEW 9 of 16 
 
 
Figure 5. Muscle insulin and protein anabolism signaling activation. Impact of previous 12-weeks 
diet-induced obesity in a mouse model after myocardial infarction-induced chronic heart failure and 
8-week pair-feeding (ObCHF) on left gastrocnemius activation in terms of relative phosphorylation 
(p/T) of (A) Insulin receptor substrate 1 (IRS-1S312), Protein kinase B (AKTS473), Glycogen synthase 
kinase 3β (GSK-3βS9) and (B) mammalian target of rapamycin (mTORS2448), Proline-rich AKT substrate 
protein (PRAS40T246) and Ribosomal protein S6 kinase (P70S6KT421/S424) to total protein ratio compared 
to previously lean (LCHF) and to lean sham operated animals (Sham). p < 0.05 among groups not 
sharing a letter, mean ± standard error of mean (SEM), n = 8/group. 
4. Discussion 
The current study demonstrated that in a MI-induced rodent model of CHF with reduced 
ejection fraction: (1) CHF leads to low gastrocnemius skeletal muscle mass with derangements of 
muscle metabolic pathways regulating tissue energy metabolism and mass maintenance; the latter 
include impaired mitochondrial ATP production, higher superoxide generation selectively at 
mitochondrial level with pro-oxidative redox state, pro-inflammatory changes in cytokine profile and 
lower insulin signaling; (2) obesity per se does not worsen CHF-induced metabolic derangements, 
but rather appears to play a paradoxically protective role with higher gastrocnemius muscle mass 
and mitochondrial ATP production, as well as preserved mitochondrial superoxide generation, tissue 
Figure 5. Muscle insulin and protein anabolis signaling activation. Impact of previous 12-weeks
diet-induced obesity in a mouse model after myocardial infarction-induced chronic heart failure and
8-week pair-feeding (ObCHF) on left gastrocnemius activation in terms of relative phosphorylation
(p/T) of (A) Insulin receptor substrate 1 (IRS-1S312), Protein kinase B (AKTS473), Glycogen synthase
kinase 3β (GSK-3βS9) and (B) mammalian target of rapamycin (mTORS2448), Proline-rich AKT substrate
protein (PRAS40T246) and Ribosomal protein S6 kinase (P70S6KT421/S424) to total protei ratio compared
to previously lean (LCHF) and to lean sham operated animals (Sham). p < 0.05 among groups not
sharing a letter, mean ± standard error of mean (SEM), n = 8/group.
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4. Discussion
The current study demonstrated that in a MI-induced rodent model of CHF with reduced ejection
fraction: (1) CHF leads to low gastrocnemius skeletal muscle mass with derangements of muscle
metabolic pathways regulating tissue energy metabolism and mass maintenance; the latter include
impaired mitochondrial ATP production, higher superoxide generation selectively at mitochondrial
level with pro-oxidative redox state, pro-inflammatory changes in cytokine profile and lower insulin
signaling; (2) obesity per se does not worsen CHF-induced metabolic derangements, but rather appears
to play a paradoxically protective role with higher gastrocnemius muscle mass and mitochondrial
ATP production, as well as preserved mitochondrial superoxide generation, tissue redox state,
cytokine profile and insulin signaling. Our findings therefore identify paradoxical and potentially
favorable obesity-associated skeletal muscle metabolic patterns, that likely contribute to preserve
skeletal muscle mass and may thereby provide a novel metabolic basis for the obesity-induced survival
advantage reported in CHF.
The study provides a comprehensive investigation of previously-reported metabolic derangements
that potentially cluster to contribute to loss of skeletal muscle mass in CHF. In lean animals, we clearly
show that CHF has a negative impact on energy metabolism with mitochondrial dysfunction both
in terms of ATP and superoxide production, thereby likely directly contributing to altered redox
state, altered cytokine profile and lower insulin signaling activation. The negative role of obesity as
a risk factor for chronic heart failure is well established [49–51], but in recent years, a more complex
relationship has emerged and a survival advantage, defined as obesity paradox, has been reported for
obese individuals in CHF as well as other chronic diseases [33,34,49,52]. The current results provide
new insight on potential mechanisms underlying the obesity paradox, by demonstrating that obesity
per se may prevent derangements in skeletal muscle energy metabolism and tissue-catabolic pathways
that characterize CHF-induced loss of skeletal muscle mass and ultimate worsening of patient outcomes
and survival.
The current findings in obese CHF animals, while novel and partly unexpected, are notably
in agreement with previous reports that obesity and may not impair and could indeed result in
enhanced skeletal muscle mitochondrial oxidative function and biogenesis, at least in the early stages
of weight gain [38,39]. Elevated fat substrates could also per se directly enhance mitochondrial ATP
production [29], and excess fatty acids may also indeed characterize obesity independently of dietary
intake [37,53]. Lower mitochondrial superoxide production is consistent with higher mitochondrial
quality in obese compared to lean CHF, as indicated by higher ATP production rates, and these
improvements could also potentially reflect improved mitochondrial dynamics (fusion and fission
processes) [18,54]. Although obesity has been reported to lead to enhanced mitochondrial fission that
may contribute to its metabolic complications, previous studies also suggested that fatty acids may
indeed reduce cardiac muscle mitochondrial fragmentation [55–57]. Differential effects of CHF and
obesity per se on different sources of superoxide are an additional intriguing finding of our study.
At variance with the obese CHF group, altered tissue redox state in lean CHF animals appears to
primarily involve enhanced superoxide production at mitochondrial level, with additional increments
in NOS superoxide production. In obese CHF, higher total muscle superoxide production did not
involve mitochondria, while suggesting a specific role for xanthine oxidase. The less pronounced
impact of differential ROS sources on tissue redox state as reflected by GSSH-GSH ratio in obese CHF
could be due at least in part to lower absolute ROS amounts generated in vivo at the xanthine oxidase
than mitochondrial level [58], to higher activation of antioxidant defenses [59], or both. Future studies
should be designed to directly address this question.
Improved tissue redox state likely causally contributed to improve pro-inflammatory cytokine
patterns as well as insulin signaling activation [27,28,60,61]. Interestingly, our data show that the
improved muscle cytokine profile observed in obese CHF mice is characterized by higher expression
of anti-inflammatory IL-10 rather than to lower pro-inflammatory Il-1β and TNFα. This finding is
in agreement with previous studies reporting beneficial effects of increased IL-10 skeletal muscle
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levels on insulin resistance in obese mice [62]. Also consistent with the current results in obese CHF,
early paradoxical increments in insulin signaling protein activation have been notably reported in
experimental high-fat diet-induced obesity models, even in the presence of elevated circulating blood
glucose and systemic insulin resistance [40–42]. Mediators downstream of mTOR including P70S6K and
PRAS40 are directly involved in activating skeletal muscle protein synthesis [63,64], and their activating
phosphorylation was enhanced in obese CHF mice even beyond levels observed in non-CHF animals.
This pattern is likely to directly contribute to higher skeletal muscle mass in obese CHF, and further
studies should be designed to identify and characterize the molecular mechanisms of this effect.
It should also be pointed out that obese animals indeed showed hyperglycemia compared to both sham
and CHF lean groups, thereby indicating that lack of gastrocnemius mass loss and muscle metabolic
derangements did not completely prevent systemic metabolic alterations that may characterize the
obesity phenotype. Hyperglycemia in obese CHF animals could have resulted from impaired insulin
action in non-skeletal muscle tissues including liver and adipose tissue, or from differential metabolic
alterations in different skeletal muscle groups. Overall, moderately elevated blood glucose also further
demonstrates that the obese phenotype was fully developed in the obese CHF group even after a
period of pair-feeding, further supporting the potential clinical and pathophysiological relevance of
the current results.
Higher gastrocnemius mass in obese CHF animals was observed both in absolute terms and
relative to body weight. Higher muscle mass is notably important for its potential translational
implications, since loss of skeletal muscle is an independent negative prognostic factor in CHF as
well as in other chronic disease conditions [65–67]. As discussed above, anti-catabolic effects of
improved redox state, cytokine patterns and insulin signaling are likely to directly contribute to higher
gastrocnemius mass in the current obese CHF model [27,28,60,61]. It should also be noted that higher
skeletal muscle mass has been demonstrated in healthy human cohorts with increasing body mass
index [43,68], likely reflecting high nutrient availability and elevated muscle workload from higher
body weight. Muscle weight could not be measured before induction of heart failure in the current
model, and it is likely that higher muscle mass preceded the onset of catabolic conditions in obese
CHF animals. The above combined observations support the hypothesis that obesity-associated higher
muscle mass may be preserved after the onset of chronic disease by less catabolic patterns of tissue
energy metabolism, oxidative stress, inflammation and insulin signaling.
We designed the study to investigate the impact of obesity per se, by pair-feeding obese CHF
animals to the same nutrient intake as lean counterparts. This approach is clinically pertinent,
since major clinical guidelines recommend dietary control of cardiovascular risk factors following
cardiovascular events through a reduction in saturated fat calories [69,70]. The selected dietary
approach notably allowed to avoid the potential confounding metabolic effects of persistent high-fat
feeding, since high-fat feeding per se and chronic high-fat diet-induced obesity have been reported
to negatively affect mitochondrial function, mitochondrial dynamics, ROS generation and tissue
inflammation [28,29,37]. It is indeed well possible that continuing high-fat feeding after CHF induction
could result in independent derangement of these metabolic pathways with loss of potentially beneficial
impact of obesity per se, or that further increments in body weight and body fat independently lead to
deleterious muscle metabolic alterations. Our overall results suggest that clinical recommendations
to limit dietary calories and fat in obese patients with CHF could also extend their potential benefits
to preservation of skeletal muscle mass. Future studies should investigate further optimization of
nutritional treatment for maintenance of skeletal muscle mass in obese CHF, with particular regard
to optimal calorie-protein ratio and additional muscle-anabolic effect of selective elevation of dietary
protein [71].
Some limitations of the study should finally be discussed. First, we did not include an obese sham
non-CHF group. However, the current study was not designed to directly assess potential specific
alterations induced by obesity in healthy animals and to compare the extent of the obesity impact in
healthy and CHF animals, but rather to investigate whether muscle metabolic parameters and different
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muscle masses are involved in, and might therefore contribute to explaining, the reported clinical
advantages in obese compared to lean patients in the context of CHF. Second, we did not measure
muscle function parameters. While skeletal muscle mass and function are generally related, changes in
one parameter following specific interventions do not necessarily predict the other, since function may
be affected by altered neuromuscular signaling and muscle contractile quality [72,73]. We therefore
cannot assume proportional changes occurring in muscle function and mass in the current model;
skeletal muscle mass preservation has however independent clinical relevance, based on previous
demonstrations that muscle mass loss per se is associated with negative outcomes in CHF patients [65]
as well as other disease conditions [66,67].
In conclusion, our findings demonstrate that CHF negatively affects skeletal muscle mitochondrial
function in lean rodents with lower ATP and higher mitochondrial ROS production, associated with
tissue pro-inflammatory cytokine profile, lower insulin signaling and muscle mass loss. Following the
onset of CHF, obesity per se is associated with higher skeletal muscle mass and tissue ATP production,
lower mitochondrial ROS production, improved redox state, cytokine profile and insulin signaling.
The current results identify paradoxical and potentially favorable obesity-associated metabolic patterns
that could contribute to reported obesity-induced survival advantage in CHF.
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